IHC - AE1/AE3

IHC – AE1/AE3 Test

The IHC AE1/AE3 Test is an advanced immunohistochemistry (IHC) diagnostic test used to detect cytokeratin proteins in tissue samples. AE1/AE3 is a broad-spectrum cytokeratin marker commonly used by pathologists to identify epithelial-origin tumors, helping distinguish carcinomas from non-epithelial cancers such as sarcomas, lymphomas, or melanomas.

Cytokeratins are structural proteins found in epithelial cells that line organs, glands, and body surfaces. When abnormal growth or cancer is suspected, detecting these proteins helps determine whether the tumor originated from epithelial tissue.

The AE1/AE3 antibody panel reacts with multiple cytokeratin subtypes, making it highly valuable for identifying poorly differentiated carcinomas, metastatic tumors, occult primary cancers, and difficult-to-classify neoplasms.

This test is usually performed on FFPE (Formalin-Fixed Paraffin-Embedded) tissue biopsy samples using advanced antibody staining methods. The stained tissue is examined microscopically by expert pathologists to determine cytokeratin expression patterns and support accurate diagnosis.

AE1/AE3 testing plays a critical role in cancer diagnosis, tumor classification, staging evaluation, and treatment planning.

Benefits of the Test

• Detects epithelial-origin tumors accurately
• Helps classify poorly differentiated cancers
• Supports cancer diagnosis confirmation
• Assists identification of metastatic tumors
• Improves pathology interpretation
• Supports personalized treatment planning

Why Doctors Recommend This Test

Doctors commonly recommend the AE1/AE3 IHC Test when:

• Tumor origin is uncertain
• Poorly differentiated cancer is suspected
• Metastatic cancer source needs identification
• Routine histopathology is inconclusive
• Cancer classification requires confirmation
• Differential diagnosis is necessary
• Additional tumor marker clarification is required
• Oncology treatment planning depends on exact diagnosis

This test improves diagnostic confidence and supports evidence-based cancer management.

Preparation Before the Test

Preparation usually includes:

• Submission of FFPE tissue block or unstained slides
• Previous histopathology reports
• Relevant clinical and imaging records
• Proper tissue labeling and packaging
• Laboratory authorization documentation

No fasting or direct patient preparation is required.

Normal Reporting Time

The normal reporting time for the AE1/AE3 IHC Test is usually 4–7 working days, depending on staining and interpretation complexity.

Who Should Take This Test?

This test is recommended for:

• Patients with suspected epithelial tumors
• Individuals with unclear biopsy diagnosis
• Patients requiring cancer classification
• Individuals with metastatic tumor evaluation needs
• Oncology patients under specialist care
• Patients requiring advanced immunohistochemistry confirmation

At Focus Diagnostics Hyderabad, advanced immunohistochemistry technology and expert oncopathology specialists ensure highly accurate AE1/AE3 IHC reports for reliable diagnosis and effective cancer treatment planning.